Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glasdegib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glasdegib SCHEMBL24503991 | 1.00 | EPHX1 (0.45) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL22104131 | 1.00 | EPHX1 (0.45) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL27100349 | 1.00 | EPHX1 (0.45) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL2068480 | 1.00 | EPHX1 (0.45) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL18184932 | 1.00 | EPHX1 (0.45) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL29362720 | 0.99 | EPHX1 (0.44) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL2068016 | 0.99 | EPHX1 (0.44) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL29359798 | 0.95 | USP30 (0.41) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL18171549 | 0.95 | USP30 (0.41) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL18171548 | 0.95 | USP30 (0.41) | EPHX1NPC1RAB9AUSP30POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-4743074-A1 | METHODS OF TREATING HEMATOLOGIC CANCER | Foghorn Therapeutics Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| US-20260108503-A1 | POLYMERIC MICELLE NANOCARRIERS FOR TARGETED EPIDERMAL DELIVERY OF THE HEDGEHOG PATHWAY INHIBITOR TAK-441 | UNIV DE GENE DE GENEVE (CH) | 2026-04-23 | — | — | US | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4722388-A1 | PREDICTION OF AN OUTCOME OF A SUBJECT SUFFERING FROM ACUTE MYOLOID LEUKEMIA | Koninklijke Philips N.V. (NL) | 2026-04-08 | — | — | EP | claimed |
| EP-4680651-A1 | ENGINEERED IMMUNE CELLS EXPRESSING ANTI-U5 SNRNP200 ANTIBODIES AND USES THEREOF | Memorial Sloan-Kettering Cancer Center (US) | 2026-01-21 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2022119349-A1 | COMPOSITION FOR SUPPRESSING RESISTANCE TO KRAS INHIBITOR | 울산대학교 산학협력단 | 2022-06-09 | — | — | WO | claimed |
| WO-2022120064-A1 | METHODS FOR IDENTIFYING LILRB-BLOCKING ANTIBODIES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-09 | — | — | WO | claimed |
| WO-2022093919-A1 | INHIBITORS OF EXO1 IN COMBINATION WITH OTHER CANCER DRUGS TO INHIBIT CANCER CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022093789-A1 | SMALL MOLECULE INHIBITORS OF APEX, ALONE AND IN COMBINATION WITH OTHER CANCER DRUGS TO INHIBIT GROWTH OF CANCER CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022087188-A1 | NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVATIVE PRODUCTS | IMMUNE-ONC THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| EP-3986388-A1 | CANNABINOID CONJUGATE MOLECULES | Diverse Biotech, Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| EP-3976036-A1 | METHODS AND USES FOR TREATING CANCER | Nelum Corporation (US) | 2022-04-06 | — | — | EP | claimed |
| US-20220071982-A1 | METHODS AND USES FOR TREATING CANCER | NELUM CORPORATION | 2022-03-10 | — | — | US | claimed |
| WO-2022029782-A1 | LONG ACTING ANTICANCER COMPOSITIONS | INTRAGEL THERAPEUTICS LTD. (IL) | 2022-02-10 | — | — | WO | claimed |
| WO-2022026360-A2 | MONOCLONAL ANTIBODIES AGAINST LILRB1 FOR DIAGNOSTIC AND THERAPEUTIC USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | EPHX1 2119/4885NPC1 3054/4885RAB9A 680/4885 |
| US-20220071982-A1 | METHODS AND USES FOR TREATING CANCER | GLI1, SHH, VHL | EPHX1 2578/4885NPC1 141/4885RAB9A 1179/4885 |
| US-20260108503-A1 | POLYMERIC MICELLE NANOCARRIERS FOR TARGETED EPIDERMAL DELIVERY OF THE HEDGEHOG PATHWAY INHIBITOR TAK-441 | SHH, SMO, GLI1 | EPHX1 2740/4885NPC1 2789/4885RAB9A 1098/4885 |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | SGMS2, SGMS1, LIPA | EPHX1 2370/4885NPC1 41/4885RAB9A 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.